Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Stockholders Equity of $466.05 million for the year ending 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +151.3% in Stockholders Equity from 2024 to 2025.
- This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 25, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: $9.05 million | Q2 2011: $10.63 million | Q4 2011: $16.17 million | Q1 2012: $12.24 million | Q2 2012: $9.37 million | Q4 2012: $8.97 million | Q1 2013: $5.31 million | Q2 2013: $34.96 million | Q4 2013: $82.73 million | Q1 2014: $191.40 million | Q2 2014: $186.36 million | Q4 2014: $146.26 million | Q1 2015: $144.75 million | Q2 2015: $131.30 million | Q4 2015: $92.92 million | Q1 2016: $74.48 million | Q2 2016: $59.98 million | Q4 2016: $97.76 million | Q1 2017: $93.89 million | Q2 2017: $90.10 million | Q4 2017: $70.75 million | Q1 2018: $114.27 million | Q2 2018: $102.31 million | Q4 2018: $172.06 million | Q1 2019: $201.20 million | Q2 2019: $226.23 million | Q4 2019: $500.08 million | Q1 2020: $494.12 million | Q2 2020: $493.14 million | Q2 2022: $453.93 million | Q4 2022: $377.04 million | Q1 2023: $446.77 million | Q2 2023: $364.83 million | Q4 2023: $160.41 million | Q1 2024: $483.79 million | Q2 2024: $330.55 million | Q4 2024: $52.59 million | Q1 2025: $683.32 million | Q2 2025: $522.31 million | Q3 2025: $466.05 million | Q4 2025: $568.42 million.
- Over the full 15 years of available data (2011 to 2025), ARROWHEAD PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 3,543.6%.
- Historical annual values: Fiscal year 2025: $466.05 million | Fiscal year 2024: $185.44 million | Fiscal year 2023: $271.34 million | Fiscal year 2022: $398.52 million | Fiscal year 2021: $408.82 million | Fiscal year 2020: $461.78 million | Fiscal year 2019: $244.59 million | Fiscal year 2018: $95.80 million | Fiscal year 2017: $81.42 million | Fiscal year 2016: $95.58 million | Fiscal year 2015: $110.18 million | Fiscal year 2014: $166.54 million | Fiscal year 2013: $27.50 million | Fiscal year 2012: $10.01 million | Fiscal year 2011: $12.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: